Estimation of the presence of cardiovascular events and direct costs associated with chronic obstructive pulmonary disease in an ambulatory setting [2];Estimación de la presencia de eventos cardiovasculares y costes directos asociados a la enfermedad pulmonar obstructiva crónica en un ámbito ambulatorio

Medicina Clinica

Volumn 128, Issue 8, 2007, Pages 317-318

  Mainar, Antoni Sicras ^a   Artieda, Ruth Navarro ^b   De Bobadilla, Jaime Fernández ^c   Vargas, Mercedes García ^c  

^a Badalona Serveis Assistencials   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; LETTER;

EID: 34147223095     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(07)72573-3     Document Type: Letter

References (10)

1. Jaén Díaz JI, Castro Mesa C, Gontán García-Salamanca MJ, López de Castro F. Prevalencia y factores de riesgo de EPOC en fumadores y ex fumadores. Arch Bronconeumol. 2003;39:554-8.
2. Izquierdo JL, De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. J COPD. 2004; 1:215-23.
3. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE Study Group. Costs of chronic bronchitis and COPD. Chest. 2003;123:784-91.
4. Izquierdo-Alonso JL, Arroyo-Espliguero R. EPOC y riesgo cardiovascular. Arch Bronconeumol. 2005;41:410-2.
5. Soriano JB, Vestbo J, Pride NB. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2003;21:559-60.
6. Sin DD, Man SF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005;83:8-13.
7. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-9.
8. Arroyo-Espliguero R, Avanzas P, Kaski JC. Enfermedad cardiovascular aterosclerótica: la utilidad de la proteína C reactiva en la identificación de la placa vulnerable y del paciente vulnerable. Rev Esp Cardiol. 2004;57:375-8.
9. Miravitiles M. La calidad de vida en los pacientes con enfermedad pulmonar obstructiva crónica: criterios de cuantificación y repercusiones terapéuticas. Rev Clin Esp. 2005;205:439-42.
10. Sackett D, Rosenberg W, Gray J, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.